Approvable Letter Delays Release of Novartis Diabetes Drug

Drug Industry Daily
KEYWORDS Clinical Trials / FDA
A A

The FDA’s request for more information on Novartis’ Type 2 diabetes treatment Galvus could significantly delay the drug’s release, the company said.

To View This Article:

Login

Subscribe To Drug Industry Daily